BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA
Announcement of FDA Filing: Biofronterra has announced the acceptance of its supplemental new drug application by the FDA.
Drug Focus: The application is specifically for Ameluz® PDT, which is intended for the treatment of superficial basal cell carcinoma.
Trade with 70% Backtested Accuracy
Analyst Views on BFRIW
No data
About the author
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT
Study Overview: A Phase 2 study has been conducted to evaluate the effects of a treatment on inflammatory acne lesions.
Results: The study shows a significant reduction in inflammatory acne lesions with the use of the treatment, Ameluz PDT.
BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS
Positive Phase 2 Results: BioFrontier AI has reported positive results from Phase 2 trials supporting the development of its AmeLuz® photodynamic therapy.
Targeted Condition: The therapy is aimed at treating moderate to severe acne vulgaris, indicating a potential advancement in acne treatment options.
BIOFRONTERA INC ANTICIPATES SUPPLEMENTAL NDA FILING FOR EXTREMITY, NECK, AND TRUNK INDICATION IN Q3 2026
- Supplemental Indication: A new supplemental indication for the treatment of extremities, neck, and trunk is expected to be submitted in Q3 2026.
- Focus on Extremities: The indication aims to address specific medical needs related to extremities, neck, and trunk conditions.
BIOFRONTERA INC. REPORTS COMPLETION OF DATABASE LOCK FOR PHASE 1 PHARMACOKINETICS STUDY OF AMELUZ® IN TREATING ACTINIC KERATOSES ON TRUNK AND EXTREMITIES
Announcement of Study: BioFrontier AI has announced a study focusing on the pharmacokinetics of a Phase 1 drug, specifically a formulation for Actinic Keratosis.
Target Condition: The study aims to evaluate the drug's effectiveness on trunk and extremities affected by Actinic Keratosis.
BIOFRONTERA INC PLANS TO SUBMIT PHASE 2B DATA FOR AMELUZ PDT TO FDA IN Q3 2026
Project Overview: The BioFrontier AI initiative is set to present Phase 2 data for the Ameluz PDT treatment in Q3 2026.
Focus on Ameluz: The data presentation will specifically highlight the efficacy and outcomes of Ameluz in photodynamic therapy (PDT).
BIOFRONTERA INC - AMELUZ PDT SHOWS POSITIVE SAFETY RESULTS IN PHASE 2B TRIAL
Study Overview: A Phase 2 study by BioFrontier AI demonstrates a favorable safety profile for a new treatment.
Implications for Treatment: The findings suggest potential advancements in therapeutic options based on the study's results.
BIOFRONTERA INC - PHASE 2B STUDY DEMONSTRATES SIGNIFICANTLY LOWER INFLAMMATORY ACNE LESIONS WITH AMELUZ PDT
Study Overview: A Phase 2 study has been conducted to evaluate the effects of a treatment on inflammatory acne lesions.
Results: The study shows a significant reduction in inflammatory acne lesions with the use of the treatment, Ameluz PDT.
BIOFRONTERA INC. ANNOUNCES ENCOURAGING PHASE 2B RESULTS FOR CONTINUED DEVELOPMENT OF AMELUZ® PHOTODYNAMIC THERAPY IN TREATING MODERATE TO SEVERE ACNE VULGARIS
Positive Phase 2 Results: BioFrontier AI has reported positive results from Phase 2 trials supporting the development of its AmeLuz® photodynamic therapy.
Targeted Condition: The therapy is aimed at treating moderate to severe acne vulgaris, indicating a potential advancement in acne treatment options.
BIOFRONTERA INC ANTICIPATES SUPPLEMENTAL NDA FILING FOR EXTREMITY, NECK, AND TRUNK INDICATION IN Q3 2026
- Supplemental Indication: A new supplemental indication for the treatment of extremities, neck, and trunk is expected to be submitted in Q3 2026.
- Focus on Extremities: The indication aims to address specific medical needs related to extremities, neck, and trunk conditions.
BIOFRONTERA INC. REPORTS COMPLETION OF DATABASE LOCK FOR PHASE 1 PHARMACOKINETICS STUDY OF AMELUZ® IN TREATING ACTINIC KERATOSES ON TRUNK AND EXTREMITIES
Announcement of Study: BioFrontier AI has announced a study focusing on the pharmacokinetics of a Phase 1 drug, specifically a formulation for Actinic Keratosis.
Target Condition: The study aims to evaluate the drug's effectiveness on trunk and extremities affected by Actinic Keratosis.
